Serum hsa_circ_0087776 as a new oncologic marker for the joint diagnosis of multiple myeloma. Issue 2 (20th December 2021)

• Record Type: Journal Article
• Authors: Gong, Xingxing; Lu, Xu; Cao, Jing; Liu, Huan; Chen, Hongmei; Bao, Fang; Shi, Xiuying; Cong, Hui
• Is Part Of: Bioengineered. Volume 12:Issue 2(2021)
• Page Start: 12447
• Page End: 12459
• Publication Date: 2021-12-20
• Subjects: Multiple myeloma -- hsa_circ_0087776 -- biomarker -- serum -- diagnosis -- quantitative real-time PCR; Biomedical engineering -- Periodicals; Biotechnology -- Periodicals; Microbiology -- Periodicals; 660.6
• DOI: 10.1080/21655979.2021.2005875
• Languages: English
• ISSNs: 2165-5987

Abstract

ABSTRACT: Multiple myeloma (MM) is a hematologic malignancy caused by abnormal proliferation of bone marrow plasma cells, which lacks diagnostic markers and has a general prognosis. At present, the understanding of its pathogenesis provides the basis for the combined diagnosis and new targeted therapy of the disease. In this study, quantitative real-time PCR was used to detect 136 MM patients and 74 healthy controls, and the clinical application value of hsa_circ_0087776 as a new tumor marker and combined diagnosis was evaluated. The results showed that the expression of hsa_circ_0087776 was significantly lower in serum of MM patients ( P -value < 0.0001), and the expression was consistent in MM cells. In the analysis of clinicopathological parameters, it was found that there were significant statistical differences with MM stage and renal injury. In addition, it significantly increased the sensitivity with ALB, β₂-MG joint diagnosis, to provide a basis for diagnosis, improve the prognosis of the disease, improve the survival of patients and quality of life. These studies suggest that hsa_circ_0087776 can be used as a new oncology marker for the combined diagnosis of MM. Impact statement: Various evidences have shown that the role of circRNA in the occurrence and development of diseases is potentially unknown and untapped. Therefore, it has a broad prospect to find circRNA specifically expressed in MM patients for combined diagnosis and targeted therapy of MM. However, MM lacks such specific tumor markers. Therefore, the discovery of new specific tumor markers for combined diagnosis is an important milestone in the development of medical history. In the research, we founded hsa_circ_0087776 can be used as a new oncology marker for combined diagnosis of MM.